Effects of ethinyl estradiol plus desogestrel on premenstrual symptoms in Iranian women.
AbstractMarvelon®, a combined oral contraceptive, contains 30 μg ethinyl estradiol (EE) and 150 μg desogestrel (DE), and has been shown to be a well-tolerated and effective combination that provides high contraceptive reliability and good cycle control. However, its efficacy has not been yet evaluated among Iranian women. Thus, the study aimed to determine the effect of oral contraceptive pill on treating premenstrual symptoms and on various parameters associated with well-being and health in a sample of Iranian. This clinical trial (before- after) study was performed at the family-planning clinic of the centers under the supervision of Tehran University of Medical Sciences on sixty-one women. The study protocol was approved by the Ethics Committee of Tehran University of Medical Sciences and all participants received a 21/7-day regimen of oral contraceptive containing 150 μg desogestrel (DE) and 30 μg ethinyl estradiol (EE) for six cycles. Efficacy parameters included changes in premenstrual symptoms were also assessed. Clinical data was collected by calendar of premenstrual experiences (COPE) at baseline and treatment cycles 1,2, 3 and 6. Clinical variables were measured including low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglyceride levels for two timing periods (baseline and last visit). Linear mixed model analyses were used to analyze differences in changes of the four factors of premenstrual syndrome (PMS), weight and blood pressure during these timing periods. The mean age of the women was 28.52 (SD=6.75) years. Participants on average had been pregnant 1.13 (SD=1.16) times. The linear mixed model analyses indicated that premenstrual syndrome symptoms reduced significantly over time (P0.05). A combined oral contraceptive containing ethinyl estradiol and desogestrel has a positive effect on women's health and reduces premenstrual symptoms.
Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined withdrospirenone or desogestrel on carbohydrate metabolism. Contraception 2003;67(6):423-9.
Berga SL. Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette. Am J Obstet Gynecol 1998;179(1):S9-17.
Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 1995;51(1):3-12.
Van den Broek AJ, van Brokhoven C, Hobbelen PMJ, et al. 11-Alkylidine steroids in the 19-nor series. Recl Trav Chim Pays Bas 1975;94(2):35-9.
van der Vies J, de Visser J. Endocrinological stidiues with desogestrel. Arzneimittelforschung 1983;33(2):231-6.
McClamrock HD, Adashi EY. Pharmacokinetics of desogestrel. Am J Obstet Gynecol 1993;168(3 Pt 2):1021-8.
Petition to Ban Third Generation Oral Contraceptives Containing Desogestrel. Public citizen. (Accessed in Jun 2014, 2, at http://www.citizen.org/hrg1799#_starend).
Population Reports/Oral Contraceptive an Update. (Accessed in Jan 2014, 12, at https://www.k4health.org/sites/default/files/Oral%20Contr aceptives-%20A9.pdf).
Koetsawang S, Charoenvisal C, Banharnsupawat L, et al. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception 1995;51(4): 225-9.
Balaha MH, Amr MA, Saleh Al Moghannum M, et al. The phenomenology of premenstrual syndrome in female medical students: a cross sectional study. Pan Afr Med J 2010;5(1):4.
Nourjah P. Premenstrual syndrome among teacher training university students in Iran. J ObstetGynecol India 2008;58(1):49-52.
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives are containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012;2:CD006586.
Mortola JF, Girton L, Beck L, et al. Diagnosis ofpremenstrual syndrome by a simple prospective and reliable instrument: the calendar of premenstrual experiences. Obstet Gynaecol 1990;76(2):302-7.
Walling M. A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol. Contraception 1992;46(4):313-26.
Sanam M, Ziba O. Desogestrel+ethinylestradiol versus levonorgestrel+ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change. Saudi Med J 2011;32(1):23-6.
Zhao J, Li Y, Wu Y, et al. Impact of different contraceptive methods on quality of life in rural women of the Jiangsu province in China. Contraception 2009;80(2):180-6.
Bäckström T, Hansson-Malmström Y, Lindhe BA, Cavalli-Björkman B, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations.Contraception 1992;46(3):253-68.
Bilotta P, Favilla S. Clinical evaluation of a monophasicethinylestradiol/desogestrel-containing oral contraceptive. Drug Res 1988;38(7):932-4.
Åkerlund M, Almström E, Högstedt S, et al. Oral contraceptive tablets containing 20 and 30 μg of ethinyl estradiol with 150 μgdesogestrel: Their influence on lipids,= lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand 1994;73(2):136-43.
Burkman RT. Lipid metabolism effects with desogestrelcontaining oral contraceptives. Am J Obstet Gynecol 1993;168(3 Pt 2):1033-40.
Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord. 2011;12(2):63-75.
Gaspard UJ, Buret J, Gillain D, et al. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception 1985;31(4):395-408.